% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

  • techtrader79 techtrader79 Mar 7, 2013 2:04 PM Flag

    Expecting a climb into the close.

    Let's face it, IMUC has a market cap that is extremely undervalued for a one of a kind Glioblastoma vaccine that turns in 18+ months of progression free survival. That's worth at least $1 Billion in market cap. Plus their IIb trial will allow them to submit and NDA to the FDA this year. This is $14-18 stock easy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The only part that I disagree with is that we will not reach 64 deaths in Q4 of this year. All the officers know this; however, at this time, being blinded to the results, they cannot yet promise that much efficacy.

      • 1 Reply to discoduck33
      • Disco, I re-ran my previous projections based on all of the numbers and assumptions given in the call and the enrollment curve vs randomization and came up with a trial reaching 32 events right about end of March. I pushed it back to zero advantage and 32'd in Nov of 12. I then pushed it up to 36 months and got 32 events in June with barely enough time to get the report in q2. What I have not been able to do yet is show 64 events in 2013 (more like March of 14) and that is without any curve separation. I just don't think we be done in this year. But the hype when we're not is going to be a blast!

    • do you think we hit 14-18 by end of year ? thnx

0.123+0.003(+2.08%)Sep 23 4:02 PMEDT